Feinberg School of Medicine of Northwestern University, 710 North Lake Shore Drive, Abbott Hall, 11th Floor, Chicago, IL 60611, USA.
Curr Treat Options Neurol. 2006 Nov;8(6):496-502. doi: 10.1007/s11940-006-0039-1.
The epidemiologic link between increased low-density-lipoprotein (LDL) cholesterol and ischemic stroke is controversial. However, recent trials make it clear that LDL reduction by statin agents in high-risk patients reduces the risk of ischemic stroke. The risk of first stroke is reduced within 1 to 2 years of statin therapy in patients at high risk for ischemic vascular disease. Patients with any history of cerebrovascular disease who are treated with statins have a reduced risk of coronary ischemic events and of all major vascular ischemic events, independent of any history of coexisting coronary artery disease. In particular, patients with recent transient ischemic attack or ischemic stroke show significantly reduced risks of both recurrent stroke and coronary events when they are treated with high-dose statin therapy. Most patients with ischemic cerebrovascular disease should be placed on statin drugs. However, most stroke patients are not currently treated to recommended levels with these agents, providing ample room for improvement in physician performance.
低密度脂蛋白(LDL)胆固醇升高与缺血性卒中之间的流行病学关联存在争议。然而,最近的试验清楚地表明,他汀类药物降低高危患者的 LDL 可降低缺血性卒中的风险。在缺血性血管疾病高危患者中,他汀类药物治疗 1 至 2 年内首次卒中的风险降低。有脑血管疾病史的患者接受他汀类药物治疗可降低冠状动脉缺血事件和所有主要血管缺血事件的风险,而与是否存在并存的冠状动脉疾病无关。特别是,近期短暂性脑缺血发作或缺血性卒中的患者接受高剂量他汀类药物治疗时,卒中复发和冠状动脉事件的风险显著降低。大多数缺血性脑血管病患者应服用他汀类药物。然而,目前大多数卒中患者并未用这些药物达到推荐水平,医生的表现还有很大的提升空间。